Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review

0301 basic medicine herpesviruses Medicine (General) R Case Report latent virus reactivation 03 medical and health sciences R5-920 COVID‐19 anti‐viral medication Medicine acyclovir long COVID
DOI: 10.1002/ccr3.8162 Publication Date: 2023-11-17T08:57:06Z
ABSTRACT
Key Clinical MessageFindings here imply lingering of virus, SARS‐CoV‐2, in the body for months. Thus, Nitazoxanide and/or other anti‐viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally.AbstractLong COVID or post‐acute sequelae of COVID‐19 (PASC) continues to affect many people even after a relatively mild acute illness. Underlying causes of PASC are poorly understood. There is no particular treatment or management program developed yet. Thus, the possibility of well‐known, safe anti‐viral medications use against PASC is proposed here.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (84)
CITATIONS (0)